|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 August 2000, Vol. 96, No. 4, pp. 1605-1607
BRIEF REPORT
Immune response to the ALK oncogenic tyrosine kinase in
patients with anaplastic large-cell lymphoma
Karen Pulford,
Brunangelo Falini,
Alison H. Banham,
Diana Codrington,
Helen Roberton,
Christopher Hatton, and
David Y. Mason
From the Nuffield Department of Clinical Laboratory Sciences
and the Department of Haematology, John Radcliffe Hospital, Oxford, UK;
Institute of Hematology, Perugia University, Perugia, Italy.
Oncogenic anaplastic lymphoma kinase (ALK) fusion proteins
(nucleophosmin-ALK [NPM-ALK] and other variants) are
expressed in many cases of anaplastic large-cell lymphoma (ALCL) but
are absent from normal tissues. The possibility that ALK proteins are
immunogenic was investigated with the use of an immunocytochemical technique to screen plasma from ALK-positive ALCL on transfectants expressing ALK proteins and by an in vitro kinase assay. Circulating antibodies against NPM-ALK protein were present in all ALK-positive ALCL patients (11 out of 11 cases) studied while 10 patients also had
antibodies recognizing normal ALK protein. Weak antibodies reactive
with NPM-ALK (which may represent anti-NPM autoantibodies) were
detected by the in vitro kinase assay in 3 of the 10 control samples
(but not by immunocytochemistry). The presence of anti-ALK antibodies
may be relevant to the relatively good prognosis of ALK-positive ALCL.
The immunocytochemical technique for detecting anti-ALK activity is
simple and semiquantative and may provide a means of detecting B-cell
responses to other tumor-associated molecules.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Brugieres, H. Pacquement, M.-C. Le Deley, G. Leverger, P. Lutz, C. Paillard, A. Baruchel, D. Frappaz, B. Nelken, L. Lamant, et al.
Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology
J. Clin. Oncol.,
October 20, 2009;
27(30):
5056 - 5061.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Marzec, Q. Zhang, A. Goradia, P. N. Raghunath, X. Liu, M. Paessler, H. Y. Wang, M. Wysocka, M. Cheng, B. A. Ruggeri, et al.
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
PNAS,
December 30, 2008;
105(52):
20852 - 20857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Pulford, C. Damm-Welk, B. Burkhardt, M. Zimmerman, A. Reiter, K. Ait-Tahar, and W. Woessmann
Circulating Antibodies to ALK Inversely Correlat with Relapse Risk and Circulating Tumor Cells in Children and Adolescents with ALK-Positive Anaplastic Large Cell Lymphoma
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
2831 - 2831.
[Abstract]
|
|
|
|
|
|
|
K. Ait-Tahar, M. C.N. Barnardo, and K. Pulford
CD4 T-Helper Responses to the Anaplastic Lymphoma Kinase (ALK) Protein in Patients with ALK-Positive Anaplastic Large-Cell Lymphoma
Cancer Res.,
March 1, 2007;
67(5):
1898 - 1901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kasprzycka, M. Marzec, X. Liu, Q. Zhang, and M. A. Wasik
From the Cover: Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3
PNAS,
June 27, 2006;
103(26):
9964 - 9969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J J Oudejans, R L ten Berge, and C J L M Meijer
Immune escape mechanisms in ALCL
J. Clin. Pathol.,
June 1, 2003;
56(6):
423 - 425.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V Costes-Martineau, C Delfour, S Obled, L Lamant, G-P Pageaux, P Baldet, P Blanc, and G Delsol
Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case report and literature review
J. Clin. Pathol.,
November 1, 2002;
55(11):
868 - 871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Passoni, A. Scardino, C. Bertazzoli, B. Gallo, A. M. L. Coluccia, F. A. Lemonnier, K. Kosmatopoulos, and C. Gambacorti-Passerini
ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes
Blood,
March 15, 2002;
99(6):
2100 - 2106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Falini and D. Y. Mason
Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry
Blood,
January 15, 2002;
99(2):
409 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
Blood,
December 1, 2000;
96(12):
3681 - 3695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
